Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dendreon Corp.

www.dendreon.com

Latest From Alfa Wassermann SPA

Scrip 100: The Architecture Of A Top Heavy Industry

Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.

Commercial Market Intelligence

Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns

Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.

Japan Reimbursement

PIPELINE WATCH: New Diabetes Therapy Studied In China, DARPins Progress In Eye Disease

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Japan Approvals Include Keytruda, First Asia Nod for Iclusig

A large batch of new drugs, indications and formulations just granted approval in Japan includes Keytruda and the first marketing authorization in Asia for Ariad's Iclusig.

Approvals Japan
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Activated Cell Therapy
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dendreon Corp.
  • Senior Management
  • W. Thomas Amick, Pres. & CEO
    Gregory R Cox, Interim CFO
    Andrew S Sandler, MD, EVP, CMO
  • Contact Info
  • Dendreon Corp.
    Phone: (877) 256-4545
    1208 Eastlake Ave. E
    Seattle, WA 98102
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register